

Achaogen  
Investor Relations Department  
7000 Shoreline Court,  
3rd Floor  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#) 

## NASDAQ: AKAO


Last Trade:	19.93
Trade Time:	4:00 PM ET Jul 26, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	3.55 - 27.79
Volume	2

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE. In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent a... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Jul 27, 2017*  
[Achaogen to Host Conference Call and Webcast of Second Quarter 2017 Financial Results on August 3, 2017](#)
- Jul 25, 2017*  
[Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections](#)
- Jul 24, 2017*  
[Achaogen Announces New Employment Inducement Grants](#)
- Jul 13, 2017*  
[Achaogen Appoints Dr. Karen Bernstein to its Board of Directors](#)
- Jun 22, 2017*  
[Achaogen Announces New Employment Inducement Grants](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Mar 14, 2017*  
[Annual Report \(10-K\)](#)
- Apr 26, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2016*  
[Quarterly Report \(10-Q\)](#)